Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Illinois: - Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
- Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
- Northwestern Medicine Glenview Outpatient Center — Glenview, Illinois
- Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Illinois: - Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Illinois: - Local Institution - 007-883-A — Arlington Heights, Illinois
- Local Institution - 007-955 — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- USOR - Illinois Cancer Specialists - Niles — Niles, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Illinois: - Illinois Cancer Specialists — Arlington Heights, Illinois
- Illinois CancerCare- Bloomington — Bloomington, Illinois
- Illinois Cancer Specialists — Chicago, Illinois
- Illinois CancerCare Galesburg — Galesburg, Illinois
- Accellacare of Duly — Lisle, Illinois
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Illinois: - Clinical Study Site — Carterville, Illinois
- Clinical Study Site — Chicago, Illinois
- Clinical Study Site — Chicago, Illinois
- Clinical Study Site — Evanston, Illinois
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Illinois: - City of Hope, Chicago — Chicago, Illinois
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Illinois at Chicago — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- Captain James A. Lovell Federal Health Care Center — North Chicago, Illinois
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Illinois: - University of Illinois Cancer Center — Chicago, Illinois
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Illinois: - Illinois Cancer Specialists — Arlington Heights, Illinois
- Local Institution - 0676 — Chicago, Illinois
- Local Institution - 0683 — Springfield, Illinois
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Illinois: - Orchard Healthcare Research, Inc. - 1116 — Skokie, Illinois
- Springfield Clinic - The Cancer Center - 1110 — Springfield, Illinois
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in Illinois: - Research Site — Elmhurst, Illinois
- Research Site — Maywood, Illinois
- Research Site — Naperville, Illinois
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Illinois: - Northwest Oncology & Hematology — Barrington, Illinois
- Elmhurst Hospital Nancy Knowles Cancer Center — Elmhurst, Illinois
- Edward Cancer Center — Naperville, Illinois
- Cancer Treatment Centers of America (CTCA) — Zion, Illinois
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Illinois: - Northwestern University — Chicago, Illinois
- University of Illinois Hospital and Health Sciences System — Chicago, Illinois
- Duly Health and Care - Lisle — Lisle, Illinois
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in Illinois: - University of Illinois Chicago — Chicago, Illinois
- Illinois Cancer Specialists — Niles, Illinois
Phase 2, Phase 3 Recruiting Industry
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…
Sponsor: AbbVie
NCT ID: NCT06236438
Sites in Illinois: - The University of Chicago Medical Center /ID# 262259 — Chicago, Illinois
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Illinois: - Orchard Healthcare Research Inc. ( Site 0115) — Skokie, Illinois
Phase 2, Phase 3 Recruiting Network
The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT04093167
Sites in Illinois: - The University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Illinois: - Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Illinois: - Rush University Medical Center Rush University Cancer Center Chicago — Chicago, Illinois
- University of Illinois at Chicago — Chicago, Illinois
- Cancer Care Specialists of Central Illinois — Decatur, Illinois
- Hope and Healing Cancer Services — Hinsdale, Illinois
- Illinois Cancer Specialists — Niles, Illinois
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Illinois: - University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
- University of Chicago Medicine-Orland Park — Orland Park, Illinois
Phase 2 Recruiting Industry
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Sponsor: Genentech, Inc.
NCT ID: NCT04302025
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
- Northwestern Medicine Cancer Center Delnor — Geneva, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Illinois: - Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Cancer Care Center of O'Fallon — O'Fallon, Illinois
- HSHS Saint Elizabeth's Hospital — O'Fallon, Illinois